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Preliminary studies showing the use of reflectance confocal microscopy for this purpose has yielded promising results. 3 We report the potential use of dermoscopy as a handy ancillary tool for the evaluation of vitiligo activity. In this case series, 78 patients with vitiligo were included. The clinical classification of disease activity was based on the definition for stability issued by the Indian Association of Dermatology, Venereology and Leprology Task Force: ''a patient reporting no new lesions, no progression of existing lesions, and absence of Koebner phenomenon during the past one year.'' 2 Of the 78 patients, 40 patients qualified for unstable, 20 stable (untreated), and 18 repigmenting vitiligo. The 18 patients with repigmenting vitiligo were on a combination treatment of topical corticosteroids, topical tacrolimus, and phototherapy. Dermoscopy was performed on the most recent lesion, as per patient recollection or (90%) cases of unstable and 3 of 20 (15%) cases of stable vitiligo. Specific dermoscopic features exclusively observed in lesions from those with unstable disease included the starburst appearance, comet tail appearance, and tiny pearly white globules (Fig 1) . White globules were also observed in clinically normalappearing perilesional skin of patients with unstable vitiligo. Leukotrichia, seen in 11 of 20 (55%) cases of stable vitiligo, correlated with treatment refractoriness (Fig 2) . Perilesional hyperpigmentation (66.7%, 12/ 18) and intralesional or perilesional erythema and telangiectasias (50%, 9/18) were exclusively seen in patients responding to treatment (Fig 2) .
Chuh and Zawar suggested that depigmentation with residual reservoirs of perifollicular pigment signify focally active or repigmenting vitiligo. 4 Meng et al reported residual PFP to be more common in patients with progressive vitiligo. 5 Our observations suggest that the retention or loss of the perifollicular pigment is an important dermoscopic marker of vitiligo activity, with PFP typifying unstable vitiligo and perifollicular depigmentation suggesting stable disease. Our results warrant confirmation through follow-up of surgical outcome in patients dermoscopically classified as stable and fit for surgery. Drug survival of secukinumab in real-world plaque psoriasis patients: A 52-week, multicenter, retrospective study To the Editor: Although secukinumab emerged as a leader in psoriatic therapy, its loss of efficacy may occur earlier and at higher rates than previously shown in phase III randomized controlled trials (RCTs). 1 The purpose of the present study was to assess the efficacy and safety of secukinumab beyond week 12 and determine whether real-world patients with psoriasis experience long-term outcomes similar to those of individuals enrolled in RCTs.
Following approval by the local research ethics committee, we performed a multicenter retrospective chart review of patients with psoriasis who were 18 years of age or older with a Psoriasis Area and Severity Index (PASI) score of 10 or higher at treatment baseline. All patients received secukinumab 300 mg at time 0, 1, 2, 3, and 4, followed by monthly maintenance dosing thereafter. The clinically significant end point for efficacy was the proportion of subjects who achieved a 75% or greater reduction in PASI from baseline (PASI 75) or Physician Global Assessment (PGA) score of 0 (clear) or 1 (almost clear) when PASI was not documented. Safety was quantified by using reported adverse events (AEs). Patients were treated and followed at 2 academic dermatology clinics in Toronto, Ontario, Canada, and end points were assessed by staff dermatologists at weeks 12 and 52 or at time of treatment discontinuation.
All 41 patients included in our analysis had moderate-to-severe plaque psoriasis, achieved PASI 75 or PGA 0/1 at week 12, and were followed up to week 52 or time of secukinumab discontinuation (Table I) Our results suggest that fewer patients treated with secukinumab maintain a PASI 75 response at week 52 (rate in the present study, 68.3%) than outlined in RCTs (FIXTURE, 84.3%; ERASURE, 80.5%; and SCULPTURE, 78.2%). 2, 3 This may, in part, be due to patient dissatisfaction following minor disease relapse. It appears that a shift in patient expectations to achieve PASI 90 or 100 has become more common, driving higher rates of discontinuation in real-world clinical practice. 4 Despite this, our results, according to which loss of efficacy occurred at 40.0 weeks, do not support previous findings reporting loss of efficacy occurs considerably earlier (according to Huang et al, at 24-32 weeks) than seen with most other biologics (at 44.8 weeks with infliximab, 42.0 weeks with ustekinumab, 33.3 weeks with adalimumab, and 22.4 weeks with etanercept). 1, 5 Similar to RCTs, AEs following 12 weeks of treatment were uncommon (n ¼ 7 [17.1%]). Commonly reported AEs included diarrhea (n ¼ 2 [4.9%]) and respiratory tract infection (nasopharyngitis and bronchitis) (n ¼ 2 [4.9%]). Notably, 1 individual experienced 3 separate episodes (in weeks 21, 35, and 39) of vomiting, diarrhea, fever, abdominal pain, and bloody stool. Similarly, 1 patient experienced irregular episodes of diarrhea throughout the 52-week treatment period. Despite early findings suggesting that secukinumab may
